Document is current
Any future updates will be listed below
-
Authors
Herdman, Michael https://orcid.org/0000-0003-0423-6005
Kerr, Cicely
Pavesi, Marco
Garside, Jamie
Lloyd, Andrew
Cubi-Molla, Patricia
Devlin, Nancy
-
Funding
Funding for this research was provided by:
Janssen-Cilag Ltd
- License Information
-
More Information
Article History
Received: 19 June 2019
Accepted: 26 February 2020
First Online: 27 March 2020
Ethics approval and consent to participate
: This secondary analysis study re-used data originally collected as part of a clinical trial. The RAY MCL3001 clinical trial (NCT01646021) was conducted according to the principles of the Declaration of Helsinki and the Guidelines for Good Clinical Practice and informed consent was obtained from all individual participants. Prior to use in this study, personally identifiable and treatment data were removed so that analysis was conducted on an anonymised and pooled data-set.
: Not applicable.
: OHE Consulting Ltd. was paid a fixed price by Janssen-Cilag Ltd. to design and conduct this study. Mike Herdman, Patricia Cubi Molla, and Nancy Devlin are or were employees of The Office of Health Economics at the time the study was conducted. Marco Pavesi and Andrew Lloyd were contracted by OHE Consulting Ltd. to conduct analysis and provide consulting input to the study. Cicely Kerr and Jamie Garside are current employees of Janssen-Cilag Ltd.
